Pegaptanib in the treatment of wet, age-related macular degeneration.
Age-related macular degeneration (AMD) is a major cause of severe visual loss worldwide. Neovascular (wet) AMD accounts for 90% of the visual loss associated with the disorder and vascular endothelial growth factor (VEGF) has been shown to play a major role in neovascularization and vascular permeability, the major causes of visual loss in AMD, making it an ideal target for therapeutic intervention. To utilize this strategy, pegaptanib, an aptamer that specifically binds to and blocks VEGF165, the VEGF isoform primarily responsible for abnormal vascular growth and permeability in AMD, was developed. Following encouraging preclinical trials, clinical trials showed that pegaptanib stabilized vision and reduced the risk of severe visual loss in the majority of patients with AMD, with some patients showing visual improvement. Pegaptanib has maintained a good safety profile with only occasional adverse effects. Even greater success was achieved when pegaptanib was used in combination with another therapeutic strategy, such as photodynamic therapy or bevacizumab, a pan isoform VEGF inhibitor. Further investigation of pegaptanib for the therapy of wet AMD, particularly in combination with other modes of therapy, should be encouraged.
Vinores
Stanley A
SA
Wilmer Eye Instutute, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287-9289, USA. svinores@jhmi.edu
D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib
Am J Pathol. 2001 Mar;158(3):1161-72
11238064
Retina. 2002 Apr;22(2):143-52
11927845
J Cell Physiol. 2006 Mar;206(3):749-58
16245301
J Chromatogr B Biomed Sci Appl. 1999 Sep 10;732(1):203-12
10517237
Arch Ophthalmol. 2004 Apr;122(4):477-85
15078664
Am J Ophthalmol. 2006 Jan;141(1):200-1
16387003
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):855-68
8603870
In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):533-42
10548435
J Biol Chem. 1998 Aug 7;273(32):20556-67
9685413
Expert Opin Pharmacother. 2005 Jul;6(8):1421-3
16013991
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18902-7
16357200
Graefes Arch Clin Exp Ophthalmol. 1997 Mar;235(3):159-67
9085111
Br J Ophthalmol. 1996 Apr;80(4):363-6
8703891
Arch Ophthalmol. 1984 Nov;102(11):1640-2
6208888
Arch Ophthalmol. 2003 Nov;121(11):1621-4
14609922
Retina. 2005 Oct-Nov;25(7):815-27
16205558
Invest Ophthalmol Vis Sci. 1994 Nov;35(12):3974-9
7525506
Retina. 2005 Dec;25(8):1065-84
16340538
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):290-9
12506087
Graefes Arch Clin Exp Ophthalmol. 1997 May;235(5):313-9
9176680
Invest Ophthalmol Vis Sci. 1996 Aug;37(9):1929-34
8759365
Invest Ophthalmol Vis Sci. 2003 May;44(5):2155-62
12714656
Drugs. 2005;65(11):1571-7; discussion 1578-9
16033295
Mol Vis. 1999 Nov 03;5:27
10562651
Pharm Res. 2000 Dec;17(12):1503-10
11303960
Nat Med. 2003 Jun;9(6):669-76
12778165
Am J Ophthalmol. 2004 Jul;138(1):91-108
15234287
Curr Opin Mol Ther. 2003 Dec;5(6):673-9
14755895
Ophthalmology. 2003 May;110(5):979-86
12750101
N Engl J Med. 2004 Dec 30;351(27):2805-16
15625332